Radiolabeled carbohydrated somatostatin analogs: A review of the current status

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 231-244

  Wester, Hans Jürgen ^a   Schottelius, Margret ^a   Poethko, Thorsten ^a   Bruus Jensen, Kjerstin ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Peptide; Peptide receptor imaging (PRI); Peptide receptor radionuclide therapy (PRRT); PET; Pharmacokinetics

Indexed keywords

CARBOHYDRATE; FLUORINE 18; GALACTOSE; GALACTOSE S OCTREOTIDE[3 TYROSINE 8 THREONINE] I 125; GLUCOSE; GLUCOSE S OCTREOTIDE[3 TYROSINE 8 THREONINE] I 125; OCTREOTIDE; OCTREOTIDE[1 DEXTRO PHENYLALANINE] 2 FLUOROPROPIONYL F 18; OCTREOTIDE[3 IODO 3 TYROSINE]; OCTREOTIDE[3 TYROSINE 8 THREONINAMIDE] GLUCOSE I 125; OCTREOTIDE[3 TYROSINE 8 THREONINAMIDE] I 125; OCTREOTIDE[3 TYROSINE 8 THREONINAMIDE] MALTOTRIOSE I 125; OCTREOTIDE[3 TYROSINE 8 THREONINE] GLUCOSE I 125; OCTREOTIDE[3 TYROSINE 8 THREONINE] GLUCURONIDE I 125; OCTREOTIDE[3 TYROSINE 8 THREONINE] I 125; OCTREOTIDE[3 TYROSINE 8 THREONINE] MALTOSE I 125; OCTREOTIDE[3 TYROSINE 8 THREONINE] MALTOTRIOSE I 124; OCTREOTIDE[3 TYROSINE 8 THREONINE] MALTOTRIOSE I 125; OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID INDIUM IN 111; OCTREOTIDE[3 TYROSINE] GLUCOSE I 125; OCTREOTIDE[3 TYROSINE] I 125; OCTREOTIDE[3 TYROSINE] MALTOSE I 125; OCTREOTIDE[3 TYROSINE] MALTOTRIOSE I 125; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER LOCALIZATION; CANCER SCINTISCANNING; CHO CELL; CONCENTRATION RESPONSE; CONFERENCE PAPER; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG SELECTIVITY; HUMAN; IC 50; INTERNALIZATION; ISOTOPE LABELING; NONHUMAN; PEPTIDE RECEPTOR IMAGING; PEPTIDE RECEPTOR RADIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIODINATION; RADIOISOTOPE DISTRIBUTION; RECEPTOR AFFINITY;

CARBOHYDRATES; HUMANS; ISOTOPE LABELING; RADIOPHARMACEUTICALS; SOMATOSTATIN;

EID: 2542491004     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323072011     Document Type: Conference Paper

References (92)

1. Signore A, Annovazzi A, Chianelli M, et al. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001;28:1555.
2. Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45:189.
3. De Jong M, Kwekkeboom D, Valkema R, et al. Radiolabeled peptides for tumor therapy: Current status and future directions. Eur J Nucl Med Mol Imaging 2003; 30:463.
4. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localization and therapy with radiopeptides. Curr Med Chem 2000;7:971.
5. Chen J, Cheng Z, Miao Y, et al. Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting. Cancer 2002;94(suppl.):1196.
6. Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte-stimulating hormone analogue. Nucl Med Biol 1997;24:171.
7. Weber WA, Haubner R, Vabuliene E, et al. Tumor angiogenesis targeting using imaging agents. Q J Nucl Med 2001;45:179.
8. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61:1781.
9. Haubner R, Wester HJ, Reuning U. Radiolabeled alpha(v)beta3 integrin antagonists: A new class of tracers for tumor targeting. J Nucl Med 1999;40:1061.
10. Baidoo KE, Lin KS, Zhan Y, et al. Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjugate Chem 1998;9:218.
11. 2 in ovarian carcinoma induced to express the gastrin-releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med 1997;38:1221.
12. 99mTc(I)-labeled bombesin analog for imaging of gastrin-releasing peptide receptor-positive tumors. Nucl Med Biol 2002;29:553.
13. Schubiger PA, Allemann-Tannahill L, Egli A. Catabolism of neurotensins: Implications for the design of radiolabeling strategies of peptides. Q J Nucl Med 1999; 42:155.
14. 99m)Tc. J Nucl Med 2002;43:374.
15. 18F-labeled neurotensin(8-13) analogs. Nucl Med Biol 2002;29:61.
16. 90Y-DOTA-TOC. J Nucl Med 2002;43:610.
17. 90Y-DOTA-TOC) in the treatment of neuroendocrine tumours: A clinical phase II study. Ann Oncol 2001;12:941.
18. 3]octreotate in a rat liver micrometastases model. Int J Cancer 2003;104:374.
19. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med 2002;43:617.
20. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor-expressing malignancies. Biopolymers 2002;66:399.
21. Behr TM, Behe M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor-binding peptides: Preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 1999;5(suppl. 10): 3124S.
22. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029.
23. Okarvi SM. Recent progress in fluorine-18 labeled peptide radiopharmaceuticals. Eur J Nucl Med 2001;28: 929.
24. 1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: Synthesis, radiolabeling, in vitro validation, and biodistribution in mice. Nucl Med Biol 1994;21:819.
25. Wester HJ, Brockmann J, Rosch F. PET-pharmacokinetics of 18F-octreotide: A comparison with 67Ga-DFO- and 86Y-DTPA-octreotide. Nucl Med Biol 1997; 24:275.
26. 18F-labeled human C-peptide: Evaluation in monkeys using positron emission tomography. Life Sci 2002;71:1361.
27. Wester HJ, Hamacher K, Stocklin G. A comparative study of N.C.A. fluorine-18 labeling of proteins via acylation and photochemical conjugation. Nucl Med Biol 1996;23:365.
28. 18F]fluorobenzoate. Int J Rad Appl Instrum 1992;19:275.
29. 5-enkephalins containing hydrophilic or hydrophobic moieties. Biopolymers 1983;22:575.
30. Garcìa-Antòn JM, Torres JL, Valencia G, et al. Synthesis and biological activity of enkephalin-related glycopeptides. In Theodoropoulos D, ed. Peptides 1986, Berlin: Walter de Gruyter & Co.: 1987;393.
31. 5]enkephalin derivatives containing D-glucose. Int J Pept Protein Res 1988;31:499.
32. 5]enkephalin-related glycoconjugates with amide type of linkage. Int J Pept Protein Res 1992;39:12.
33. Horvat S, Horvat J, Varga-Defterdarovic L, et al. Methionine-enkephalin-related glycoconjugates: Synthesis and biological activity. Int J Pept Protein Res 1993; 41:399.
34. Cudic M, Horvat J, Elofsson M, et al. Synthesis and cistrans isomerism in novel Leu-enkephalin-related peptidomimetics containing N-glycated glycine residues. J Chem Soc Perkin Trans 1998;1:1789.
35. Polt R, Porreca F, Szabó L. Glycopeptide enkephalin analogs produce analgesia in mice: Evidence for penetration of the blood-brain barrier. Proc Natl Acad Sci USA 1994;91:7114.
36. Kriss CT, Lou BS, Szabò LZ, et al. Tetrahedron Asymm 2000;11:9.
37. Williams SA, Abbruscato TJ, Szabò L, et al. Biology and Physiology of the Blood-Brain Barrier. New York, Plenum Press: 1996.
38. Egleton RD, Mitchell SA, Huber JD. Improved bioavailability to the brain of glycosylated Met-enkephalin analogs. Brain Res 2000;37:881.
39. Egleton RD, Mitchell SA, Huber JD. Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. J Pharmacol Exp Ther 2001;299:967.
40. Harrison AW, Fisher JF, Guido DM, et al. Appraisal of a glycopeptide cloaking strategy for a therapeutic oligopeptide: Glycopeptide analogs of the renin inhibitor ditekiren. Bioorg Med Chem 1994;2:1339.
41. Fisher JF, Harrison AW, Bundy GL, et al. Peptide to glycopeptide: Glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties. J Med Chem 1991;34:3140.
42. Kihlberg J, Ahman J, Walse B. Glycosylated peptide hormones: Pharmacological properties and conformational studies of analogues of [1-desamino, 8-D-arginine]vasopressin. J Med Chem 1995;38:161.
43. Nomoto M, Yamada K, Haga M, et al. Improvement of intestinal absorption of peptide drugs by glycosylation: Transport and tetrapeptide by the sodium ion-dependent D-glucose transporter. J Pharm Sci 1998;87:326.
44. Shirota K, Kato Y, Suzuki K, et al. Characterization of novel kidney-specific delivery system using an alkyglucoside vector. J Pharmacol Exp Ther 2001;299:459.
45. Suzuki K, Susaki H, Okuno S, et al. Renal drug targeting using a vector "alkylglycoside." J Pharmacol Exp Ther 1999;288:57.
46. Suzuki K, Susaki H, Okuno S, et al. Specific renal delivery of sugar-modified low-molecular-weight peptides. J Pharmacol Exp Ther 1999;288:888.
47. Suzuki K, Ando T, Susaki H, et al. Structural requirements for alkylglycoside-type renal targeting vector. Pharm Res 1999;16:1026.
48. Terasaki T, Mizukuchi C, Itoho L, et al. Hepatic uptake of octreotide, a long-acting somatostatin analogue, via a bile acid transport system. Hepatology 1995;20: 191.
49. Ziegler K, Lins W, Frimmer M. Hepatocellular transport of cyclosomatostatins: Evidence for a carrier system related to the multispecific bile acid transporter. Biochem Biophys Acta 1991;1061:287.
50. Bertrams A, Ziegler K. Hepatocellular uptake of peptide by bile acid transporter: Relationship of carrier-mediated transport of linear peptides with renin-inhibiting activity of multispecific bile acid transporters. Biochem Biophys Acta 1991;1091:337.
51. Nakamura T, Hisaka A, Sawasaki Y. Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist into rat hepatocyte. J Pharmacol Exp Ther 1996;278:564.
52. Yamada T, Niiuma K, Lemaire M, et al. Carrier-mediated hepatic uptake of the cationic cyclopeptide, octreotide, in rats. Drug Metab Dispos 1996;25:536.
53. Albert R, Marbach P, Bauer W, et al. SDZ CO 611: A highly potent glycated analog of somatostatin with improved oral activity. Life Sci 1993;53:517.
54. Fricker G, Dubost V, Schwab D, et al. Heterogeneity in hepatic transport of somatostatin analog octapeptides. Hepatology 1994;20:191.
55. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326.
56. 18F-labeled sstr-binding SPECT/PET tracers with improved biodistribution. J Labeled Cpd Radiopharm (abstr.) 1999;42:549.
57. Krenning EP, Bakker WH, Breeman WA, et al. Localization of endocrine-related tumors with radioiodinated analog of somatostatin. Lancet 1989;i:242.
58. Bakker WH, Breeman WA, van der Pluijm ME, et al. Iodine-131-labeled octreotide: Not an option for somatostatin receptor therapy. Eur J Nucl Med 1996;23: 775.
59. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: Radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31:1501.
60. Bakker WH, Krenning EP, Breeman WA, et al. In vivo use of a radioiodinated somatostatin analogue: Dynamics metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 1991;32:1184.
61. 3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20: 716.
62. O'Connor MK, Kvols LK, Brown ML, et al. Dosimetry and biodistribution of a iodine-123 labeled somatostatin analog in patients with neuroendocrine tumors. J Nucl Med 1992;33:1613.
63. 3-octreotide by conjugation with carbohydrates. Bioconjugate Chem 2002;13:1021.
64. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status and future limitations. Eur J Nucl Med 1998;25:201.
65. Bernard HF, Krenning EP, Breeman WA, et al. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929.
66. de Jong M, Rolleman EJ, Bernard BF, et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388.
67. Vaidyanathan G, Friedman HS, Affleck DJ, et al. Specific and high-level targeting of radiolabeled octreotide analogs to human medulloblastoma xenografts. Clin Cancer Res 2003;9:1686.
68. Wester HJ, Schottelius M, Scheidhauer K, et al. Comparison of radioiodinated TOC, TOCA, and Mtr-TOCA: The effect of carbohydration on the pharmacokinetics. Eur J Nucl Med 2002;29:28.
69. 3-octreotate. J Labeled Compds Radiopharm 2003;46:S397.
70. Reubi JC, Wasser B, Schaer JC, et al. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836.
71. Bruns C, Lewis I, Briner U, et al. SOM230: A novel somatostatin peptidomimetic with broad somatotropin release-inhibiting factor. (SRIF) receptor-binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146:707.
72. Reubi JC, Eisenwiener KP, Rink H, et al. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002;45:456.
73. Hukovic N, Panetta R, Kumar U, et al. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology 1996;137:4046.
74. 111In-labeled somatostatin analogs for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437.
75. 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: Evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J Med Chem 1999;42:1341.
76. Reubi JC, Schär JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
77. 18F-labeled tracer suitable for routine clinical imaging of sst-receptor-expressing tumors using positron emission tomography. Clin Cancer Res in press.
78. Rueter J, Mattern RH, Zhang L, et al. Syntheses and biological activities of sandostatin analogs containing stereochemical changes in positions 6 and 8. Biopolymers 2000;53:497.
79. 3-octreotide reveals high potential of glycated and radiometalated octreotide derivatives for diagnosis and therapy. Nucl Med Commun (abstr.) 2000; 21:579.
80. Waibel R, Alberto R, Willuda J. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17:997.
81. 99mTc] (CO)3-labeled carbohydrated SSTR-ligands: Synthesis, internalization kinetics, and biodistribution on a rat pancreatic tumor model. (abstr.) J Nucl Med 2001;42: 115P.
82. 18)F-labeled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003;30:117.
83. Heppeler A, Froidevaux S, Mäcke HR, et al. Radiometal-labeled macrocyclic chelator-derivatized somatostatin analogue with superb tumor-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974.
84. Pochon S, Buchegger F, Pelegrin A, et al. A novel derivative of the chelon desferrioxamine for site-specific conjugation to antibodies. Int J Cancer 1989;43:1188.
85. Rose K. Facile synthesis of homogeneous artificial proteins. J Am Chem Soc 1994;116:30.
86. Thumshirn S, Hersel U, Goodman SL, et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-Phase peptide synthesis and chemoselective oxime ligation. Chemistry 2003;9:2717.
87. Kurth M, Pelegrin A, Rose K, et al. Site-specific conjugation of a radioiodinated phenylethylamine derivative to a monoclonal antibody results in increased radioactivity localization in tumor. J Med Chem 1993;36:1255.
88. 18F-labeled RGD- and octreotide analogs. J Nucl Med in press.
89. 18F-labeling of peptides? J Labeled Compds Radipharm 2003;46:S17.
90. 18F-labeled tracer suitable for routine clinical imaging of sst-receptor-expressing tumors using positron emission tomography. Clin Cancer Res in press.
91. Schottelius M, Poethko T, Herz M, et al. A new generation of carbohydrated F-18-labeled sst-ligands: Fast synthesis, high yields, and excellent pharmacokinetics. J Labeled Compds Radipharm 2003;46:S105.
92. Poethko T, Schottelius M, Thumshirn G. Chemoselective preconjugate labeling of unprotected mono- and multimeric peptide ligands. Radiochimica Acta in press.